Adagrasib API
Pharmaceutical Oncology
Oncology API

Adagrasib

High-purity pharmaceutical grade Adagrasib API manufactured to meet stringent USP/EP specifications for targeted cancer therapy formulations. Our pharmaceutical grade API delivers exceptional purity and consistency for critical oncology drug manufacturing applications.

  • USP/EP Grade Quality Standards
  • High Purity ≥99.0% (HPLC)
  • Comprehensive Analytical Documentation
  • Regulatory Compliance Support
  • cGMP Manufacturing Standards
  • Pharmaceutical Grade Packaging
Request Quote Technical Support

Technical Specifications

Chemical Formula: C31H31F3N6O3
CAS Number: 2230806-05-8
Molecular Weight: 604.62 g/mol
Purity (HPLC): ≥99.0% (pharmaceutical grade)
Physical State: White to off-white crystalline powder
Water Content (Karl Fischer): ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤1.0% total impurities
Particle Size (D90): ≤50 μm
Storage Conditions: Store in cool, dry place (2-8°C)
Packaging Options: 1kg, 5kg pharmaceutical containers

Applications

KRAS G12C Targeted Therapy
Oncology Drug Manufacturing
Oral Pharmaceutical Formulations
API Synthesis & Development
Cancer Research Applications
Pharmaceutical Research
Drug Product Manufacturing
Quality Control Testing
Regulatory Compliance
Clinical Trial Materials
Bioanalytical Method Development
Reference Standard Applications

Industry-Specific Grades

DRAVYOM offers specialized Adagrasib grades tailored for specific pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse drug manufacturing applications.

USP Grade (Pharmaceutical)
Purity: ≥99.0% (HPLC) Water Content: ≤0.5% Heavy Metals: ≤10 ppm Application: Pharmaceutical formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% (pharmaceutical) Related Substances: ≤1.0% Residue on Ignition: ≤0.1% Application: European market compliance
Research Grade
Purity: ≥98.0% (analytical) Water Content: ≤1.0% Particle Size: Controlled Application: R&D, method development
GMP Grade
Purity: ≥99.5% (pharmaceutical) Endotoxins: ≤2.5 EU/mg Microbial Limits: Compliant Application: Oral solid dosage forms

Quality Standards

DRAVYOM's pharmaceutical grade Adagrasib is manufactured under stringent cGMP protocols, meeting international pharmaceutical standards including USP, EP, and ICH guidelines. Our pharmaceutical-grade production ensures consistent quality and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥99.0% Pharmaceutical Purity
Advanced Analytical Testing
Comprehensive Impurity Control
Batch-to-Batch Consistency
Complete Documentation Package
Temperature-Controlled Logistics

Advanced Chemical Properties & Performance

Pharmaceutical grade Adagrasib exhibits exceptional chemical properties essential for targeted oncology therapy. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding pharmaceutical formulations and research applications.

Analytical Properties
Solubility (Water): Practically insoluble
LogP (octanol/water): 3.8 ± 0.2
pKa: 7.2 ± 0.1
UV λmax: 285 nm (methanol)
Physical Properties
Melting Point: 198-202°C
Bulk Density: 0.4-0.6 g/mL
Crystalline Form: White to off-white powder
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
Bioavailability: Food-enhanced absorption
Protein Binding: 96.4%
Half-life: 23 hours
Metabolism: Hepatic (CYP3A4)
Purity Specifications
Assay (HPLC): ≥99.0%
Related Substances: ≤1.0% total
Water Content: ≤0.5% (Karl Fischer)
Residue on Ignition: ≤0.1%
Stability Properties
Shelf Life: 3 years (unopened)
Light Sensitivity: Protect from light
Temperature Stability: Stable 2-8°C
Oxidation Sensitivity: Store under nitrogen

Performance Characteristics

Detailed performance metrics demonstrate pharmaceutical grade Adagrasib superiority in targeted cancer therapy with exceptional selectivity, precision, and reproducibility across diverse KRAS G12C inhibition protocols and research procedures.

Pharmaceutical Performance

Assay: ≥99.0% active pharmaceutical ingredient

Exceptional purity for targeted therapy
Target Selectivity

IC50: Nanomolar potency against KRAS G12C

Superior target selectivity profile
Dissolution Rate

Solubility: Optimized for bioavailability

Enhanced absorption characteristics
Thermal Stability

Working range: 2-8°C optimal storage

Maintains activity across temperature range
Batch Consistency

Variation: ±0.2% between manufacturing batches

Exceptional lot-to-lot reproducibility
Extended Stability

3 years shelf life under recommended conditions

Long-term pharmaceutical grade integrity

Safety Information

Potent oncology pharmaceutical compound requiring specialized handling procedures. Use appropriate containment measures, personal protective equipment, and follow institutional cytotoxic drug handling protocols. Avoid skin contact, inhalation, and ingestion. Handle in designated areas with proper ventilation systems.

Cytotoxic
Health Hazard
Reproductive Toxicity

Storage & Handling

Store in original containers in a cool, dry area (2-8°C) away from light and incompatible materials. Keep containers tightly closed and protect from moisture and oxidation. Use appropriate cytotoxic storage protocols and ensure proper segregation from other pharmaceutical materials.

Refrigerated storage (2-8°C)
Protect from light
Secure cytotoxic storage area
Inert atmosphere storage

Chemical Mechanisms & Reaction Pathways

Adagrasib exhibits selective KRAS G12C inhibition through covalent binding, enabling precise oncological applications with predictable pharmacokinetic pathways and quantitative tumor suppression mechanisms.

Covalent Inhibition

Irreversible binding to KRAS G12C mutant protein

Quantitative oncogene suppression
Cellular Uptake

Targeted delivery via active transport mechanisms

Essential for therapeutic efficacy
Signal Transduction

Disruption of downstream oncogenic signaling pathways

Enables selective anticancer activity
Protein Binding

Selective binding to mutant KRAS over wild-type

Targeted therapeutic approach

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical access with complete documentation packages supporting international standards and pharmaceutical manufacturing validations.

USP Specifications

United States Pharmacopeia pharmaceutical standards compliance

EP Standards

European Pharmacopoeia specifications for pharmaceutical analysis

ICH Guidelines

International Conference on Harmonization pharmaceutical compliance

FDA Registration

United States Food and Drug Administration compliance

Method Validation

Supported analytical method validation documentation

SDS Documentation

Multi-language Safety Data Sheets (16 sections, GHS compliant)

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, stability testing assistance, and regulatory services to optimize pharmaceutical grade Adagrasib performance in your specific therapeutic applications.

Formulation Development
  • Pharmaceutical formulation optimization support
  • Stability testing guidance
  • Bioavailability and bioequivalence validation
  • Custom pharmaceutical procedures
Analytical Services
  • Certificate of Analysis verification
  • Custom purity analysis
  • Impurity profiling and identification
  • Method validation support
Technical Support
  • Pharmaceutical troubleshooting consultation
  • Storage and handling guidance
  • Safety training and protocols
  • Manufacturing best practices
Supply Solutions
  • Consistent batch scheduling
  • Emergency supply arrangements
  • Custom packaging options
  • Global distribution network

Environmental Impact & Sustainability

Our pharmaceutical grade Adagrasib production emphasizes environmental responsibility through sustainable manufacturing practices, waste minimization, and comprehensive environmental impact management for pharmaceutical operations.

Waste Minimization

Optimized production with minimal waste generation

Water Treatment

Advanced wastewater treatment and recycling systems

Clean Production

Energy-efficient synthesis with emission controls

Safe Disposal

Comprehensive guidance for pharmaceutical waste management

ISO 14001

Environmental management system certified production

Container Recycling

Pharmaceutical container return and recycling programs

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent pharmaceutical grade Adagrasib quality and performance across all production batches.

Production Process

Advanced synthesis and purification in controlled cGMP environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive analytical testing protocol including purity, impurities, and stability

HPLC verification and spectroscopic analysis
Quality Systems

ISO 9001:2015 quality management with pharmaceutical manufacturing accreditation

Continuous improvement and process validation
Packaging Control

Pharmaceutical containers with controlled atmosphere packaging

Stability protection and contamination prevention

Market Applications & Performance Data

Comprehensive pharmaceutical development data demonstrating pharmaceutical grade Adagrasib effectiveness across diverse therapeutic applications with quantified performance metrics and clinical study validations.

Pharmaceutical Manufacturing
Purity: >99.5% pharmaceutical grade Bioavailability: Consistent therapeutic levels Stability: 24+ months under controlled conditions
Research Institutions
Clinical Studies: 50+ published research applications Reproducibility: >98% batch-to-batch consistency Innovation: Custom grade development
Generic Manufacturing
Regulatory Success: 100% FDA approval support Cost Efficiency: 25% reduction in manufacturing costs Quality Assurance: Zero batch failures

DRAVYOM Competitive Advantages

Superior Purity

Consistently exceeds pharmaceutical specifications with ultra-low impurities and exceptional therapeutic performance

Reliable Supply

Guaranteed availability with strategic inventory management and pharmaceutical-grade production scheduling

Pharmaceutical Expertise

Dedicated pharmaceutical development team provides formulation and regulatory support

Quality Assurance

Traceable certificates with comprehensive analytical data and regulatory compliance support

Global Standards

International compliance with USP, EP, and ICH specifications for worldwide acceptance

Partnership Approach

Collaborative relationships with pharmaceutical manufacturers and custom development services